文献速递关节外科骨质疏松与代谢性骨病骨肿瘤

血液病异基因骨髓移植后骨坏死年轻患者全髋关节置换术的长期结果:平均随访11年的多中心倾向匹配队列研究

Long-Term Results of Total Hip Arthroplasty in Young Patients With Osteonecrosis After Allogeneic Bone Marrow Transplantation for Hematological Disease: A Multicenter, Propensity-Matched Cohort Study With a Mean 11-Year Follow-Up.
PubMed 文献 · J Arthroplasty · 2020-09-14

该多中心倾向匹配队列研究比较了血液病异基因骨髓移植后骨坏死患者与特发性骨坏死患者行全髋关节置换术的长期结果。平均随访10.6±3.5年,两组临床、影像学和假体生存率及Harris髋关节评分相似,13年全因翻修生存率骨髓移植组93.4% vs 对照组95%(P=0.928)。结论认为当代非骨水泥全髋关节置换术在异基因骨髓移植后年轻血液病患者中不增加手术并发症、翻修、再手术、再入院和死亡风险。

要点

  • 骨髓移植组与特发性骨坏死组13年全因翻修生存率分别为93.4%和95%,差异无统计学意义(P=0.928)。
  • 两组再手术率(4% vs 5.3%,P=1.000)、90天再入院率(均为5.3%)和总死亡率(4.4% vs 1.7%,P=0.681)均无显著差异。
  • 两组均无假体周围感染或感染性松动,骨髓移植组无骨溶解,对照组2髋(2.7%)发生骨溶解(P=0.497)。

核心结论

  • 平均随访11年的多中心调查显示,当代非骨水泥全髋关节置换术在异基因骨髓移植后年轻血液病患者中,与匹配的特发性骨坏死队列相比,不增加手术并发症、翻修、再手术、再入院和死亡风险。

研究设计与样本

  • 多中心倾向匹配队列研究,纳入1997年至2012年在2家机构因骨髓移植后骨坏死行全髋关节置换术的所有患者。
  • 采用倾向评分按年龄、性别、体重指数、美国麻醉医师协会评分和手术年份进行1:1匹配,骨髓移植组45例患者75髋与无血液病史的特发性骨坏死组58例患者75髋匹配。
  • 手术时平均年龄36.7岁,52%为男性,末次随访时进行临床和影像学评估并获取临床评分,采用Kaplan-Meier分析比较假体生存率。

主要发现

  • 平均随访10.6±3.5年,两组临床、影像学和假体生存率结果及Harris髋关节评分相似。
  • 13年全因翻修生存率骨髓移植组为93.4%,对照组为95%(P=0.928)。
  • 再手术率骨髓移植组4% vs 对照组5.3%(P=1.000),90天再入院率两组均为5.3%,总死亡率骨髓移植组4.4% vs 对照组1.7%(P=0.681)。
  • 两组均无假体周围感染或感染性松动,骨溶解骨髓移植组0髋 vs 对照组2髋(2.7%)(P=0.497)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of young patients with hematological disease requiring total hip arthroplasty (THA) is expected to increase. We aimed to investigate the long-term THA outcomes in patients with osteonecrosis of the femoral head (ONFH) following allogeneic bone marrow transplantation (BMT) for hematological disease. METHODS: All patients who underwent THA for osteonecrosis after BMT from 1997 to 2012 were identified at 2 institutions. Using propensity scores, 75 THAs in 45 patients were matched for age, gender, body mass index, American Society of Anesthesiologists score, and year of surgery with 75 THAs in 58 patients with idiopathic ONFH without a history of hematological disease (1:1 ratio). The mean age at surgery was 36.7 years and 52% were men. Clinical and radiographic evaluations were performed and clinical scores were obtained at last follow-up. Kaplan-Meier analyses were used to compare survivorship. RESULTS: At a mean follow-up of 10.6 ± 3.5 years, clinical, radiographic, and survivorship outcomes, and the Harris hip scores were similar between both groups. The 13-year survivorship for all-cause revision was 93.4% for the BMT group and 95% for the control group (P = .928). No significant differences were observed between groups in the rates of reoperation (4% vs 5.3%, P = 1.000), 90-day readmission (all 5.3%), or overall mortality (4.4% vs 1.7%, P = .681). No hips had periprosthetic joint infection or septic loosening in either group. Osteolysis occurred in none of the BMT patients and in 2 hips (2.7%) of the control patients (P = .497). CONCLUSION: This large cohort multicenter survey at 11-year follow-up shows that contemporary cementless THA in young hematological disease patients after allogeneic BMT is not associated with a higher risk for surgical complications, revision, reoperation, readmission, and mortality compared to a matched cohort of idiopathic ONFH.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kim SC, Lim YW, Jo WL, et al. Long-Term Results of Total Hip Arthroplasty in Young Patients With Osteonecrosis After Allogeneic Bone Marrow Transplantation for Hematological Disease: A Multicenter, Propensity-Matched Cohort Study With a Mean 11-Year Follow-Up. J Arthroplasty. 2020. PMID: 33036842. doi:10.1016/j.arth.2020.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。